Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

被引:30
|
作者
Matsuda, Satoru [1 ]
Kawakubo, Hirofumi [1 ]
Okamura, Akihiko [2 ]
Takahashi, Keita [2 ]
Toihata, Tasuku [2 ]
Takemura, Ryo [3 ]
Mayanagi, Shuhei [1 ]
Hirata, Kenro [4 ]
Irino, Tomoyuki [1 ]
Hamamoto, Yasuo [4 ]
Takeuchi, Hiroya [5 ]
Watanabe, Masayuki [2 ]
Kitagawa, Yuko [1 ]
机构
[1] Keio Univ, Sch Med, Dept Surg, Tokyo, Japan
[2] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Surg Gastroenterol, Tokyo, Japan
[3] Keio Univ Hosp, Clin & Translat Res Ctr, Biostat Unit, Tokyo, Japan
[4] Keio Univ, Sch Med, Dept Internal Med, Tokyo, Japan
[5] Hamamatsu Univ, Sch Med, Dept Surg, Hamamatsu, Shizuoka, Japan
关键词
esophageal cancer; esophagectomy; multidisciplinary treatment; preoperative chemotherapy; CANCER-PATIENTS; CHEMORADIOTHERAPY; SURVIVAL; COMPLICATIONS;
D O I
10.1097/SLA.0000000000004436
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: This study aimed to elucidate the residual disease distribution and recurrence patterns in patients with ESCC responding to NAC. Summary Background Data: To appropriately plan a prospective trial for the organ preservation approach which includes additional chemoradiotherapy in patients who responded to NAC, the distribution of residual disease needs to be elucidated. Given that the residual tumor is located in the regional field, chemoradiotherapy can be safely added to eliminate the residual disease. Methods: Overall, 483 patients with resectable ESCC who received NAC followed by transthoracic esophagectomy at 2 high-volume centers were reviewed. The recurrence-free survival, overall survival (OS), and residual and recurrent tumor patterns were compared among the pathological responses. Results: Compared with nonpathological responders, pathological responders exhibited significantly longer recurrence-free survival [hazard ratio of Grade 1b/2/3 compared with Grade 0: 0.25 (P < 0.001)/0.17 (P < 0.001)/0.16 (P = 0.003)] and OS [hazard ratio of Grade 1b/2/3 compared with Grade 0: 0.26 (P < 0.001)/0.12 (P < 0.001)/0.11 (P = 0.003)]. In terms of the distribution of recurrence, the percentages of solitary recurrence in the regional field out of all recurrence was significantly higher in patients with Grade lb (60%)/2 (67%)/3 (67%) whereas less than 25% in Grade 0 or 1a. Conclusions: It was found that postoperative recurrence in responders occurred in the regional field mostly as a solitary lesion without the distant failure, indicating that the residual tumor cells can be eliminated by additional chemoradiotherapy.
引用
收藏
页码:298 / 304
页数:7
相关论文
共 50 条
  • [41] Tumor Response in Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemotherapy Followed by Surgery
    Ohsawa, Manato
    Hamai, Yoichi
    Emi, Manabu
    Takaoki, Furukawa
    Ibuki, Yuta
    Tomoaki, Kurokawa
    Yoshikawa, Toru
    Okada, Morihito
    ANTICANCER RESEARCH, 2020, 40 (02) : 1153 - 1160
  • [42] Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery
    Kitasaki, Nao
    Hamai, Yoichi
    Emi, Manabu
    Kurokawa, Tomoaki
    Yoshikawa, Toru
    Hirohata, Ryosuke
    Ohsawa, Manato
    Okada, Morithito
    IN VIVO, 2022, 36 (06): : 2852 - 2860
  • [43] Intratumoral Fusobacterium Nucleatum Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma
    Yamamura, Kensuke
    Izumi, Daisuke
    Kandimalla, Raju
    Sonohara, Fuminori
    Baba, Yoshifumi
    Yoshida, Naoya
    Kodera, Yasuhiro
    Baba, Hideo
    Goel, Ajay
    CLINICAL CANCER RESEARCH, 2019, 25 (20) : 6170 - 6179
  • [44] Prognostic significance of tumor regression grade in esophageal squamous cell carcinoma after neoadjuvant chemoradiation
    Zhang, Chi
    Xu, Fei
    Qiang, Yong
    Cong, Zhuang-Zhuang
    Wang, Qin
    Zhang, Zheng
    Luo, Chao
    Qiu, Bing-Mei
    Hu, Li-Wen
    Shen, Yi
    FRONTIERS IN SURGERY, 2023, 9
  • [45] Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma
    Cao, X. -F.
    He, X. -T.
    Ji, L.
    Xiao, J.
    Lv, J.
    DISEASES OF THE ESOPHAGUS, 2009, 22 (06) : 477 - 481
  • [46] Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study
    Zhang, Xiaobin
    Eyck, Ben M.
    Yang, Yang
    Liu, Jun
    Chao, Yin-Kai
    Hou, Ming-Mo
    Hung, Tsung-Min
    Pang, Qingsong
    Yu, Zhen-Tao
    Jiang, Hongjing
    Law, Simon
    Wong, Ian
    Lam, Ka-On
    van der Wilk, Berend J.
    van der Gaast, Ate
    Spaander, Manon C. W.
    Valkema, Roelf
    Lagarde, Sjoerd M.
    Wijnhoven, Bas P. L.
    van Lanschot, J. Jan B.
    Li, Zhigang
    BMC CANCER, 2020, 20 (01)
  • [47] Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
    Ren-Wen Huang
    Yin-Kai Chao
    Yu-Wen Wen
    Hsien-Kun Chang
    Chen-Kan Tseng
    Sheng-Chieh Chan
    Yun-Hen Liu
    World Journal of Surgical Oncology, 12
  • [48] Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma
    Yang, Xinyu
    Yin, Hao
    Zhang, Shaoyuan
    Jiang, Tian
    Gu, Jianmin
    Jiao, Heng
    Wang, Hao
    Liang, Fei
    Xu, Songtao
    Fan, Hong
    Ding, Jianyong
    Ge, Di
    Wang, Qun
    Yin, Jun
    Tan, Lijie
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2025, 169 (01)
  • [49] Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma
    Nagai, Yohei
    Yoshida, Naoya
    Baba, Yoshifumi
    Harada, Kazuto
    Imai, Katsunori
    Iwatsuki, Masaaki
    Karashima, Ryuichi
    Koga, Yuki
    Nomoto, Daichi
    Okadome, Kazuo
    Ishimoto, Takatsugu
    Imamura, Yu
    Watanabe, Masayuki
    Baba, Hideo
    DIGESTIVE ENDOSCOPY, 2020, 32 (01) : 39 - 48
  • [50] Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma
    Wenjie Ni
    Jinsong Yang
    Wei Deng
    Zefen Xiao
    Zongmei Zhou
    Hongxing Zhang
    Dongfu Chen
    Qinfu Feng
    Jun Liang
    Jima Lv
    Xiaozhen Wang
    Xin Wang
    Tao Zhang
    Nan Bi
    Lei Deng
    Wenqing Wang
    BMC Cancer, 20